Last updated on December 2019

Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)


Brief description of study

This is a multi-center, open-label, dose escalation study that will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of liposomal annamycin as a single agent for the treatment of subjects with AML that is refractory to or relapsed after standard induction therapy

Clinical Study Identifier: NCT03315039

Find a site near you

Start Over

University Hospitals Cleveland Medical Center

Cleveland, OH United States
6.32miles
  Connect »